<SEC-DOCUMENT>0001213900-24-037861.txt : 20240430
<SEC-HEADER>0001213900-24-037861.hdr.sgml : 20240430
<ACCEPTANCE-DATETIME>20240430162149
ACCESSION NUMBER:		0001213900-24-037861
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240425
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240430
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		24897618

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0204892-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:CTXR="http://citiuspharma.com/20240425">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_CTXR_citiuspharma.com_20240425 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20240425_20240425 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000004" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20240425.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-04-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-25</xbrli:startDate>
        <xbrli:endDate>2024-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_904_edei--DocumentType_c20240425__20240425_zZXhFen0IcAl"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported)
<span style="text-decoration: underline"><span id="xdx_90C_edei--DocumentPeriodEndDate_c20240425__20240425_zdo4r8AtrVL"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 25, 2024</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20240425__20240425_za9mjX8SoQQh"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000011" name="dei:EntityRegistrantName">Citius Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20240425__20240425_zBZqHFCTymp"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFileNumber_c20240425__20240425_zdA8Ysi3MAJa"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000013" name="dei:EntityFileNumber">001-38174</ix:nonNumeric></span></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20240425__20240425_zYKYplCCalO2"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer
Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20240425__20240425_zDU0I5L84hQe"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000015" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20240425__20240425_zXSjuNNHY9ol"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000016" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20240425__20240425_zTDCOh3fBC5i"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000017" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240425__20240425_zy0NoRUWRe5j"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityAddressPostalZipCode_c20240425__20240425_zUbhcuzSHxD1"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000019" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number,
including area code <span style="text-decoration: underline">(<span id="xdx_901_edei--CityAreaCode_c20240425__20240425_zjQ8n6NBzfm1"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000020" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20240425__20240425_zugNrHk17Bl8"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000021" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--WrittenCommunications_c20240425__20240425_zae9IuuqNq5"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--SolicitingMaterial_c20240425__20240425_zl8bsWgzF2Y9"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--PreCommencementTenderOffer_c20240425__20240425_zFQOyYrL2JOj"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="padding-right: 0.2in"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-right: 0.2in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20240425__20240425_zM1m5UI5ZNR1"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="padding-right: 0.2in"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Title
of each class</p></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Trading
Symbol(s)</p></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Name of each exchange</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">on which registered</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20240425__20240425_zJQpCco80jLj"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20240425__20240425_ziKCAQLBV2N9"><ix:nonNumeric contextRef="AsOf2024-04-25" id="Fact000027" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">The <span id="xdx_904_edei--SecurityExchangeName_c20240425__20240425_ztatir9WEDJj"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20240425__20240425_z8TlhuGDRdH8"><ix:nonNumeric contextRef="AsOf2024-04-25" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 25, 2024, Citius Pharmaceuticals, Inc.
(the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) <span style="background-color: white">with
certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the &#8220;Offering&#8221;),
of 21,428,574 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Shares&#8221;) and warrants (the &#8220;Warrants&#8221;)
to purchase up to 21,428,574 shares of common stock. The Shares and Warrants were sold at a combined offering price of $0.70. The Offering
closed on April 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">The Warrants
have an exercise price equal to $0.75 per share, are exercisable six months after the issuance date and will expire five years after the
initial exercise date. </span>The exercise price and number of shares of common stock issuable upon exercise are subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise
price. If there is no effective registration statement for the resale of the shares issuable upon exercise of the Warrants, holders of
Warrants may elect a &#8220;cashless&#8221; exercise, whereby they would receive the net number of shares of common stock determined according
to a formula set forth in the Warrants. On the expiration date of the Warrants, any Warrants outstanding and unexercised will be automatically
exercised via cashless exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">H.C. Wainwright and Co., LLC (&#8220;Wainwright&#8221;)
<span style="background-color: white">acted as the Company&#8217;s exclusive placement agent in connection with the Offering. In connection
with the Offering, the Company agreed to pay Wainwright a cash fee of 7.0% of the gross proceeds the Company received in the Offering.
The Company agreed to also reimburse Wainwright $100,000 for fees and expenses of legal counsel, $35,000 for non-accountable expenses
and $15,950 for a clearing fee. In addition, the Company has agreed to grant placement agent warrants to Wainwright, or its designees,
to purchase up to 1,500,000 shares of the common stock (the &#8220;Placement Agent Warrants&#8221;). The terms of the Placement Agent
Warrants are substantially the same as the terms of the Warrants, except that the exercise price is $0.875 per share and the Placement
Agent Warrants will expire five years from the commencement of sales in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The net proceeds to the
Company from the Offering were approximately $13.8 million, after deducting placement agent fees and other offering expenses payable by
the Company. The Company anticipates using the net proceeds from the Offering for general corporate purposes, including pre-clinical and
clinical development of its product candidates and working capital and capital expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Pursuant to the Purchase
Agreement, the Company agreed for a period of 45 days following the closing of the Offering not to issue, enter into an agreement to issue
or announce the issuance or proposed issuance of the shares or any other securities convertible into, or exercisable or exchangeable for,
shares of common stock, subject to certain exceptions. The Company has also agreed for a period of one year following the closing date
of the Offering not to (i) issue or agree to issue new equity or debt securities convertible into, or exercisable or exchangeable for,
shares at a conversion price, exercise price or exchange price which floats with the trading price of the shares or which may be adjusted
after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the
Company may issue securities at a future-determined price, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Offering was made
pursuant to the Company&#8217;s effective registration statement on Form S-3 (File No. 333-277319), which was previously declared effective
by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 1, 2024, including a prospectus supplement filed
with the SEC on April 26, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Purchase Agreement
contains customary representations and warranties and agreements of the Company and the investors and customary indemnification rights
and obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made solely for
the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly,
the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Purchase
Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in
conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The foregoing descriptions
of the Purchase Agreement and the Warrants are qualified in their entirety by reference to the forms of the Purchase Agreement and Warrant,
copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and are incorporated herein by reference. A copy of the opinion
of Wyrick Robbins Yates &amp; Ponton LLP relating to the legality of the issuance and sale of the Shares and the Warrants in the Offering
is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item. 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 26, 2024, the Company issued a press release
to announce the entry into the Purchase Agreement. On April 30, 2024, the Company issued a press release to announce the closing of the
Offering. The press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 9.01</b> <b>Financial Statements and Exhibits.</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (d) The following exhibits are being filed with this Current Report on Form 8-K.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1.5pt solid; width: 9%"><b>Exhibit</b></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"/><td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 90%"><b>Description</b></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td>4.1</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex4-1_citius.htm">Form of Investor Warrant issued on April 30, 2024.</a></td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: White">
<td>5.1</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex5-1_citius.htm">Opinion of Wyrick Robbins Yates &amp; Ponton LLP.</a></td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td>10.1</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex10-1_citius.htm">Form of Securities Purchase Agreement, dated as of April 25,
                                                     2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto</a>.</td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: White">
<td>23.1</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex5-1_citius.htm">Consent of Wyrick Robbins Yates &amp; Ponton LLP (included in Exhibit 5.1).</a></td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td>99.1</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex99-1_citius.htm">Press release, dated April 26, 2024.</a></td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: White">
<td>99.2</td><td style="text-align: left">&#160;</td><td style="text-align: justify"><a href="ea020489201ex99-2_citius.htm">Press release, dated April 30, 2024.</a></td></tr>
     <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td>104</td><td style="text-align: left">&#160;</td><td style="text-align: justify">Cover Page Interactive Date File (embedded within the Inline
XBRL document).</td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 60%"/><td style="text-align: justify; width: 40%"><b>CITIUS</b> <b>PHARMACEUTICALS, INC.</b></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>Date: April 30, 2024</td><td style="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Leonard Mazur</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: justify">Leonard Mazur</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: center">&#160;</td><td style="text-align: left">Chairman and Chief Executive Officer</td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUyXgvIxqYgsQiJ63XKKJd2R2c30k/rLNiUaBobh3nOvECOxppUukeG8yDM4YlWXyiHkeENGc0XvSDfbBPzN8a6tY2Vc//7AlDyDnpmGUl680FsbbbFIIJqM5XwsJxDLZDqDw04EXz0lc9MFGqdVCcoUcGCqWaNT3A0JR9WSoarrq07IVpNJIA6jQX6DjGIJe2rUi/hhIctSEYz6CcSa6Vl717J1aL4kLEusfJ0d6P8GHw1zSpg= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea020489201ex4-1_citius.htm
<DESCRIPTION>FORM OF INVESTOR WARRANT ISSUED ON APRIL 30, 2024
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Citius
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: right; width: 45%; font-size: 10pt">Issue Date: April __, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Initial Exercise Date: October __, 2024</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on ____<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated April 25, 2024, among the Company and the purchasers signatory thereto. For purposes herein,
&ldquo;<U>Spinoff</U>&rdquo; means the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of October
23, 2023, by and among the Company, Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub, Inc., which was filed as an exhibit
to the Company&rsquo;s Form 8-K filed with the Commission on October 24, 2023, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">a)&nbsp;<U>Exercise of Warrant</U>.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of
(i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i)
herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: left">Insert the date that is the five (5) year anniversary of the
Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">b)&nbsp;<U>Exercise Price</U>.
The exercise price per share of Common Stock under this Warrant shall be <B>$0.75</B>, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">c)&nbsp;<U>Cashless Exercise</U>.
If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not
available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such
time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)&nbsp;=&nbsp;</TD><TD STYLE="text-align: left"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align:left; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)&nbsp;=&nbsp;</TD><TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: -0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)&nbsp;=&nbsp;</TD><TD STYLE="text-align: left"> the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align:left; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align:left; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: left; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&ldquo;<FONT STYLE="background-color: white"><U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest
of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align:left; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">d)&nbsp;<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The
Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for
the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days (ii) the number of days comprising the Standard
Settlement Period, in each case after the delivery to the Company of the Notice of Exercise and (iii) one (1) Trading Day after
delivery of the aggregate Exercise Price to the Company (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon
delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the
Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant
Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for
each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to
accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or the Holder rescinds
such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant
remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement
period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in
effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise
delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the
time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m.
(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for
purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of
Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is
required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the
amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was
required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise
to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its
exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of
$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise
to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of
the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number
of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of
shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%] [9.99%]
of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re&#45;classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;</FONT><U>Reserved</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">c)&nbsp;<U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any
Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class
of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">d)&nbsp; <U>Pro Rata
Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">e)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) other than solely the Spinoff, the
Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other
disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of
Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the
Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of
the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section
2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the
Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with,
or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the
applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the
Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction; <U>provided</U>, <U>however</U>, if the Fundamental Transaction is not within the Company&rsquo;s control, including not
approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity,
as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion),
at the Black Scholes Value (as defined below) of the unexercised portion of this Warrant, that is being offered and paid to the
holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of
cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among
alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common
Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such
Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant
based on the Black Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P.
(&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between
the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the
announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction,
if earlier) and ending on the Trading Day of the Holder&rsquo;s request pursuant to this Section 3(e) and (D) a remaining option
time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds (or by delivery of such other consideration, as applicable) within five Business Days of the Holder&rsquo;s election
(or, if later, on the consummation date of the Fundamental Transaction).&nbsp; The Company shall cause any successor entity in a
Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a
security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the
exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price
hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant with the same effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt, the
Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient
authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to
the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">g)&nbsp; <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><U>&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">b)&nbsp;<U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">c)&nbsp;<U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">a)&nbsp;<U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise,&rdquo; and to receive the cash payments
contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net cash settle a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">b)&nbsp; <U>Loss, Theft,
Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">c)&nbsp;<U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">d)&nbsp;<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align:left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align:left; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align:left; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall be commenced
in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;). Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">h)&nbsp;<U>Notices</U>. Any
and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, Attention: <B>Jamie Bartushak, Chief
Financial Officer</B>, email address: <B>jbartushak@citiuspharma.com</B>, or such other facsimile number, email address or address as
the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided
by the Company hereunder shall be in writing and delivered personally, by facsimile or email, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, email address or address of such Holder appearing on the books of the
Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time
of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address set forth
in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile or email at the facsimile number or email address set forth in this Section on a day
that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to
the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: Citius
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0in">&#9744; in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0in">&#9744; if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: left; font-size: 10pt"><U></U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number: &nbsp; &nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Holder&rsquo;s Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Holder&rsquo;s Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea020489201ex5-1_citius.htm
<DESCRIPTION>OPINION OF WYRICK ROBBINS YATES & PONTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Wyrick Robbins Yates &amp; Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Raleigh, North Carolina 27607-7506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 30, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Citius Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11 Commerce Drive, First Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cranford, New Jersey 07016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as counsel to Citius Pharmaceuticals,
Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the issuance and sale of (i) an aggregate of 21,428,574
shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;),
(ii) warrants to purchase up to an aggregate of 21,428,574 shares of Common Stock (the &ldquo;<B>Warrants</B>&rdquo;), and (iii) placement
agent warrants to purchase up to an aggregate of 1,500,000 shares of Common Stock (the &ldquo;<B>Placement Agent Warrants</B>&rdquo;),
pursuant to the registration statement on Form S-3 (Registration Statement No. 333-277319), as filed by the Company with the Securities
and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;),
as declared effective by the Commission on March 1, 2024 (the registration statement, as it may be amended from time to time, is herein
referred to as the &ldquo;<B>Registration Statement</B>&rdquo;), together with the exhibits to the Registration Statement and the documents
incorporated by reference therein and the related base prospectus which forms a part of and is included in the Registration Statement
and the related prospectus supplement in the form filed with the Commission pursuant to Rule 424(b) under the Act on April 26, 2024 (the
&ldquo;<B>Prospectus</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Shares and the Warrants are to be sold pursuant
to a Securities Purchase Agreement, dated as of April 25, 2024, by and among the Company and the investors signatory thereto (the &ldquo;<B>Purchase
Agreement</B>&rdquo;), which has been filed as an exhibit to the Company&rsquo;s Current Report on Form 8-K filed on April 30, 2024. The
Placement Agent Warrants are to be issued pursuant to that certain engagement letter between the Company and H. C. Wainwright&nbsp;&amp;
Co., LLC dated April 10, 2024 (the &ldquo;<B>Engagement Letter</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this opinion, we have examined
and relied upon the Registration Statement and the Prospectus, the Company&rsquo;s Amended and Restated Articles of Incorporation, as
amended to date, the Company&rsquo;s Amended and Restated Bylaws, as amended to date, the Purchase Agreement, the Engagement Letter and
such instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinion hereinafter
expressed. In such examination, we have assumed: (i) the authenticity of original documents and the genuineness of all signatures; (ii)
the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information,
representations and warranties contained in the records, documents, instruments and certificates we have reviewed; and (iv) the due execution
and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon the foregoing, we are of the opinion
that (i) the Shares, when issued and sold in accordance with the Purchase Agreement, the Registration Statement and the Prospectus, will
be duly authorized, validly issued, fully paid and non-assessable, (ii) the Warrants, when issued and sold in accordance with the Purchase
Agreement, the Registration Statement and the Prospectus, will constitute valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization,
arrangement, moratorium or other similar laws affecting creditors&rsquo; rights, and subject to general equity principles and to limitations
on availability of equitable relief, including specific performance, (iii) the Placement Agent Warrants, when issued in accordance with
the Engagement Letter, the Registration Statement and the Prospectus, will constitute valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency,
reorganization, arrangement, moratorium or other similar laws affecting creditors&rsquo; rights, and subject to general equity principles
and to limitations on availability of equitable relief, including specific performance, (iv) when the shares of Common Stock underlying
the Warrants (the &ldquo;<B>Warrant Shares</B>&rdquo;) are issued and paid for in accordance with the terms and conditions of the Underwriting
Agreement and the Warrants and issued and sold in accordance with the Registration Statement and the Prospectus, the Warrant Shares will
be duly authorized, validly issued, fully paid and non-assessable, and (v) when the shares of Common Stock underlying the Placement Agent
Warrants (the &ldquo;<B>Placement Agent Warrant Shares</B>&rdquo;) are issued and paid for in accordance with the terms and conditions
of the Letter Agreement and the Placement Agent Warrants and issued and sold in accordance with the Registration Statement and the Prospectus,
the Placement Agent Warrant Shares will be duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This opinion is limited to the current federal
laws of the United States and laws of the State of Nevada, including the statutory provisions and reported judicial decisions interpreting
these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We hereby consent to the use of our name wherever
it appears in the Registration Statement and the Prospectus, and in any amendment or supplement thereto, the filing of this opinion as
an exhibit to a current report on Form&nbsp;8-K of the Company and the incorporation by reference of this opinion in the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In giving this consent, we do not admit that we
are within the category of persons whose consent is required by Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations
promulgated thereunder by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding: 0.25pt">Sincerely, &nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">/S/ WYRICK ROBBINS YATES &amp; PONTON LLP</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ea020489201ex10-1_citius.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF APRIL 25, 2024, BY AND AMONG CITIUS PHARMACEUTICALS, INC. AND THE INVESTORS SIGNATORY THERETO
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.25in"><FONT STYLE="font-variant: small-caps; text-transform: capitalize"><B>E</B></FONT><B><FONT STYLE="font-variant: small-caps; text-transform: lowercase">xhibit
10.1</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of April 25, 2024, between Citius Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended
(the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close; <U>provided</U>,
<U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay
at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure
of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo;
obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations to deliver the Securities, in each case, have been
satisfied or waived, but in no event later than the second (2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Common Warrants shall be exercisable six months from the date of issuance and have a term of exercise equal
to five (5) years following the initial exercise date, in the form of <U>Exhibit A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Wyrick Robbins Yates &amp; Ponton LLP, with offices located at 4101 Lake Boone Trail, Suite 300, Raleigh, North
Carolina 27607.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers, directors, consultants or vendors
of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee members
of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services
rendered to the Company, provided that such issuances to consultants and vendors are issued as &ldquo;restricted securities&rdquo; (as
defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
within forty-five (45) days following the Closing Date, (b) securities upon the exercise or exchange of or conversion of any Securities
issued hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon
exercise of the warrants to the Placement Agent, and/or other securities exercisable or exchangeable for or convertible into shares of
Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date
of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such
securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that
such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require
or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and
provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means each Lock-Up Agreement, dated as of the date hereof, by and between the Company and each of the directors and
officers of the Company, each in the form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals <B>$0.70</B>, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to one or more of the Purchasers at the
Closing in accordance with Section 2.2(a)(v) hereof, in the form of <U>Exhibit A-2</U> attached hereto, which Pre-Funded Warrants shall
be exercisable immediately and will expire when exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser prior to or at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-277319 which registers the sale of the Shares,
the Warrants and the Warrant Shares to the Purchasers, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Rule 462(b)
Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was
filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the
Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the Pre-Funded
Warrants purchased by such Purchaser, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Lock-Up Agreement, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, New York 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.1 <U>Closing</U>. On the Closing
Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not
jointly, agree to purchase, up to an aggregate of $15,000,000 of Shares and Common Warrants. Notwithstanding anything herein to the contrary,
to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription Amount (together with such
Purchaser&rsquo;s Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates)
would cause such Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation,
such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section 2.2(a). The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. Each Purchaser&rsquo;s
Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery
Versus Payment&rdquo; settlement with the Company or its designees. The Company shall deliver to each Purchaser its respective Shares
and a Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing
shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree. Unless otherwise directed by
the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e.,
on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer
Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent
shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent
(or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after
the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior
to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), if such Purchaser sells to any Person all, or any portion, of any Common
Stock to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser
shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally
bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Purchaser at the
Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s
receipt of the Subscription Amount for such Pre-Settlement Shares hereunder; provided, further, that the Company hereby acknowledges
and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser
will elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any shares of Common Stock will be
made in the sole discretion of such Purchaser from time to time, including during the Pre-Settlement Period. Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City
time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver
the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the
Warrant Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a legal opinion of Company Counsel, in a form reasonably acceptable to the Purchasers and the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>subject to the seventh sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(iv) subject to the
seventh sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to
deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of
Common Stock issuable upon exercise of such Purchaser&rsquo;s Pre-Funded Warrants, if applicable), registered in the name of such
Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser
to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to
Pre-Funded Warrants divided by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment
therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of
such Purchaser&rsquo;s Shares and Pre-Funded Warrants, with an exercise price equal to $0.75, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the duly executed Lock-Up Agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(a)   The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each
Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). Except as set forth
on <U>Schedule 3.1(a)</U>, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary
free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are
fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor in default of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;); provided that a change in the market price or trading volume of the Common Stock alone shall not be deemed,
in and of itself, to constitute a Material Adverse Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting
or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s
stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(d) <U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of
the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or
similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the
Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or
(iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is
bound or affected; except in the case of each of clauses (ii) and (iii), such as would not, individually or in the aggregate, have
or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) notification(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(f) <U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the
applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock
the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and
filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on March 1, 2024
(the &ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been
required prior to the date of this Agreement. The Company was at the time of the filing of the Registration Statement eligible to
use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements as set
forth in General Instruction I.B.1 of Form S-3. The Registration Statement is effective under the Securities Act and no stop order
preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has
been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are
threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus
Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became
effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or
supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of
the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U>
shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the
date hereof. Except as set forth on <U>Schedule 3.1(g)</U>, the Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the
Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee
stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the
most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result
of the purchase and sale of the Securities and as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of
Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of
any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers and the Placement Agent) and will not result in a right of any
holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no
outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion,
exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no
outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to
redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are
duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and state
securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. Except for the Required Approvals, no further approval or authorization of any stockholder, the Board of
Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements
or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus
Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates,
the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the
Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that
has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant
to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity
securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have
pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities
contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence or
development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)
adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)
would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the
Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state,
local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),
nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all applicable federal, state, local
and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the
value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the
Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in
accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the
Subsidiaries are in compliance, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of
this Agreement, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect. Neither
the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of
any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license
rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any
rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none
of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than
for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under
any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company
in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report
under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic
report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over
financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or
is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect
to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with
the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Registration Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any
Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has no
reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti&#45;takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(y) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the
Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated
hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months
preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made
any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in
Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(aa) <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital
availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it
to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its
ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its
debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or
liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule
3.1(aa)</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or
for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means
(x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for
any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Accountants</U>. The Company&rsquo;s independent registered public accounting firm is set forth on <U>Schedule 3.1(dd)</U> of
the Disclosure Schedules. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm
as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report for the fiscal year ending September 30, 2024. Other than permissible tax compliance services, such accounting firm has
not, during the periods covered by the financial statements included in the Prospectus, provided to the Company any non-audit services,
as such term is used in Section 10A(g) of the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ee) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and
the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further
represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has
been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ff) <FONT STYLE="text-decoration: double"><u>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</u></FONT><FONT STYLE="text-underline-style: double">. </FONT>Anything in this Agreement or
elsewhere herein to the contrary notwithstanding (except for Sections&nbsp;3.2(f) and 4.14 hereof), it is understood and acknowledged
by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from
purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued
by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this
or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any
Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly,
presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material compliance with applicable laws) at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the
Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the
value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being
conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(hh) <U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a
&ldquo;<U>Pharmaceutical Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested,
distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules
and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good
manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record
keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no
pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or
administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and
none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the
distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of
advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical
investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its
Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its
Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the
United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as
to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(jj) <U>Cybersecurity</U>.
(i)(x) To the knowledge of the Company, there has been no security breach or other compromise of or relating to any of the
Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including
the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it),
equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not
been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any security
breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance in all
material respects with all applicable laws, statutes or regulations, internal policies and contractual obligations relating to the
privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access,
misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect;
(iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and
protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and
Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance with Data Privacy Laws</U>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the last three
(3) years were, in compliance in all material respects with all applicable data privacy and security laws and regulations, including,
without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed
to ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the Company provides accurate
notice of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws;
and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating
to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by
Privacy Laws.&nbsp;&ldquo;<U>Personal Data</U>&rdquo; means personal data as defined by the Privacy Laws. (i)&nbsp;None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii)&nbsp;the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement by or with
any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to
the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on
each date on which it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left; text-indent: 51pt">(f) <U>Certain Transactions
and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person
acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including
Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term
sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made
to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>&#9;<U>Warrant Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement
to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued
pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available
for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and
available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability
of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities
laws). The Company shall use its best efforts to keep a registration statement (including the Registration Statement) registering the
issuance or resale of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Furnishing of Information</U>. Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have
expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(b) of the Exchange Act or to
timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act as long as the Company is then subject to the reporting requirements of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand,
and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the
Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press
release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in
which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required
by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.5 <U>Shareholder Rights Plan</U>.
No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &ldquo;<U>Acquiring
Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to
trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any
other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not
have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees
or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or
Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable
law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such material non-public information with the Commission
pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from
the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.8 <U>Indemnification of
Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such
Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted
against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who
is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents
(unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants
under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any
violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally
judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any
Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify
the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing
reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party
except to the extent that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has
failed after a reasonable period of time to assume such defense and to employ counsel or (z) in such action there is, in the
reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of
such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by a Purchaser
Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (2) to the
extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any
of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements
contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others
and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and
keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.10 <U>Listing of Common Stock</U>.
For as long as the Warrants are outstanding and exercisable, the Company hereby agrees to use reasonable best efforts to maintain the
listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the
Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all
of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock
traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such
other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly
as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a
Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules
of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company
agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements
except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms.
If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to
seek specific performance of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsequent Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until forty-five (45) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue,
enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents
or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration
statement on Form S-8 in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until the one (1) year anniversary after the Closing Date, the Company shall be prohibited from effecting
or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, after forty-five (45)
days after the Closing Date, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with
the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief
against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also
offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class
and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting
of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure
Schedules (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing, and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company or its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates, or agents, including, without limitation, the Placement Agent, after the issuance of the initial press release as described
in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above
shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Capital Changes</U>. Until the one (1) year anniversary of the Closing Date, the Company shall not undertake a reverse or forward
stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest
of the Shares, provided that no consent shall be required in the event that, following the good faith determination of the Board of Directors
that such reverse stock split is required, the Company undertakes a reverse stock split of the Common Stock for purposes of maintaining
the listing of the Common Stock on the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise
notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading
Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the
email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York
City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any
Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> </P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares
and Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser)
or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,
modification or waiver disproportionately and adversely impacts a Purchaser (or at least 50.1% in interest of such group of Purchasers),
the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transfer is in compliance with all applicable federal and state
securities laws and such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the
Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties,
and covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for
its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities
for a period of not longer than six (6) years from the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an exercise
of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice
concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration
of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the
defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in
any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and
other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Saturdays, Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.21<B>&nbsp;<U>WAIVER OF JURY
TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY
AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line"><U>Address for Notice:</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line; width: 40%">E-mail:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    Name:<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">ctxr</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; width: 40%; padding-bottom: 2pt">Name of Purchaser: </TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; layout-grid-mode: line; width: 60%; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><I>Signature of Authorized Signatory of Purchaser</I>:</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; layout-grid-mode: line; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">Name of Authorized Signatory:</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; layout-grid-mode: line; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">Title of Authorized Signatory:</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; layout-grid-mode: line; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">Email Address of Authorized Signatory:</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; layout-grid-mode: line; padding-bottom: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">Address for Notice to Purchaser:</TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; layout-grid-mode: line; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Bloc<FONT STYLE="font-family: Times New Roman, Times, Serif">ker
&#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Warrant
Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#9744; Notwithstanding anything contained in
this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this
Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed,
shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur by the second (2nd) Trading Day
following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded
by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or
purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed
(as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on
the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">38</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea020489201ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED APRIL 26, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Pharmaceuticals Announces $15 Million
Registered Direct Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Cranford, NJ, April 26, 2024</B>&nbsp;&ndash;
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) (&ldquo;Citius&rdquo; or the &ldquo;Company&rdquo;), a late-stage biopharmaceutical company
dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into
definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase
up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warrant in a registered
direct offering. The warrants will have an exercise price of $0.75 per share, will be exercisable six months from the date of issuance,
and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about April 30, 2024,
subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">H.C. Wainwright &amp; Co. is acting as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The aggregate gross proceeds to the Company from
the offering are expected to be approximately $15 million, before deducting the placement agent fees and other offering expenses payable
by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical
and clinical development of our product candidates and working capital and capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The securities described above are being offered
pursuant to a &ldquo;shelf&rdquo; registration statement (File No. 333-277319) filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on February 23, 2024 and declared effective on March 1, 2024. The offering is being made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities being offered will be filed with the SEC and be available at the SEC&rsquo;s website at www.sec.gov. Electronic copies
of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available,
by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3<SUP>rd</SUP>&nbsp;Floor, New York, NY 10022, by telephone at (212)
856-5711 or e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Citius is a late-stage biopharmaceutical company
dedicated to the development and commercialization of first-in-class critical care products. The Company&rsquo;s diversified pipeline
includes two late-stage product candidates. The Biologics License Application for LYMPHIR<SUP>TM</SUP>, a novel IL-2R immunotherapy for
an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target
action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary
asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment
in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit
www.citiuspharma.com.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements
by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
&ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking statements
are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price, and includes all statements related to the completion of the offering, the satisfaction
of customary closing conditions related to the offering and the intended use of net proceeds from the offering. Factors that could cause
actual results to differ materially from those currently anticipated are: risks related to the closing of the offering; risks relating
to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to
preclinical and clinical testing; the early stage of products under development; our need for substantial additional funds; our ability
to commercialize our products if approved by the FDA; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale
supply; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates
to impact the quality of life of our target patient populations; our ability to obtain, perform under and maintain financing and strategic
agreements and relationships; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related
to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates
and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings.
These risks have been and may be further impacted by Covid-19 and could be impacted by any future public health risks. Accordingly, these
forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these
forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC&rsquo;s
website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December
29, 2023, and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we
expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greg@STiR-communications.com</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ea020489201ex99-2_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED APRIL 30, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;Citius Pharmaceuticals Announces Closing of
$15 Million Registered Direct Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cranford, NJ, April 30, 2024</B>&nbsp;&ndash; Citius
Pharmaceuticals Inc. (Nasdaq: CTXR) (&ldquo;Citius&rdquo; or the &ldquo;Company&rdquo;), a late-stage biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced
registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase
up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warrant. The warrants
have an exercise price of $0.75 per share, will be exercisable six months from the date of issuance, and will expire five years from the
initial exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">H.C. Wainwright &amp; Co. acted as the exclusive placement
agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate gross proceeds to the Company from the
offering were approximately $15 million, before deducting the placement agent fees and other offering expenses payable by the Company.
Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical
development of our product candidates and working capital and capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities described above were offered pursuant
to a &ldquo;shelf&rdquo; registration statement (File No. 333-277319) filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on February 23, 2024 and declared effective on March 1, 2024. The offering was made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities offered was filed with the SEC and is available at the SEC&rsquo;s website at www.sec.gov. Electronic copies of the
prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting H.C.
Wainwright &amp; Co., LLC at 430 Park Avenue, 3<SUP>rd</SUP>&nbsp;Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail
at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an offer to
sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Citius is a late-stage biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products. The Company&rsquo;s diversified pipeline includes two
late-stage product candidates. The Biologics License Application for LYMPHIR<SUP>TM</SUP>, a novel IL-2R immunotherapy for an initial
indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action
date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset.
LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its
Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements
by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
&ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking statements
are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price, and includes all statements related to the intended use of net proceeds from the
offering. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results
of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and
clinical testing; the early stage of products under development; our need for substantial additional funds; our ability to commercialize
our products if approved by the FDA; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; the
estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact
the quality of life of our target patient populations; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth
strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies
successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks
have been and may be further impacted by Covid-19 and could be impacted by any future public health risks. Accordingly, these forward-looking
statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking
statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC&rsquo;s website at
www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023,
and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly
disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Investor Contact: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Greg@STiR-communications.com</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ctxr-20240425.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /Ksps7xRiXgOn8uFYHlMOaWJ6aPtzJZzuekxt2p0Hdlany8mzB5mbiMDaceWgScB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:CTXR="http://citiuspharma.com/20240425" elementFormDefault="qualified" targetNamespace="http://citiuspharma.com/20240425">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://citiuspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20240425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20240425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ctxr-20240425_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ctxr-20240425_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharma.com/role/Cover" xlink:href="ctxr-20240425.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139995231563232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 4XD-BL+H^!7 7%F/)4[KH:N 2E[P@U.87?',/]"V"153>)W;HCO^>W_AKM
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M7(W =/G',T92VKR/6_+;.I&'UV#+D@V_V%#6",TFB_O);QA3Z>_^5?[^ /W
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ N(*>6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ N(*>6 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "X
M@IY8+8PLENX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "X@IY8F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +B"GE@7676-
M500  !D1   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "X@IY8GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0204892-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctxr-20240425.xsd</File>
    <File>ctxr-20240425_lab.xml</File>
    <File>ctxr-20240425_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0204892-8k_citius.htm">ea0204892-8k_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0204892-8k_citius.htm": {
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharma.com/20240425",
   "dts": {
    "schema": {
     "local": [
      "ctxr-20240425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20240425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20240425_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0204892-8k_citius.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://citiuspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204892-8k_citius.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204892-8k_citius.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001213900-24-037861-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-037861-xbrl.zip
M4$L#!!0    ( +B"GECO]"+^+0,  .\+   1    8W1X<BTR,#(T,#0R-2YX
M<V2U5MMRVC 0?>],_T'UNVTP(4T()-.0H26%)@.YM2\=(0O01)9<20Y.OKZ2
M;UP,%&CK)WEUSME=[:[LYD4<4/""A22<M:RJ4[$ 9HC[A$U:UOW0_C1L=[L6
MN#A__P[HI_G!MD&'8.HWP!5'=I>-^1GX!@/< )\QPP(J+L[  Z21L? .H5B
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MI#V!,"S 8RA'B6BVL0260I6!VK@*LM5KB.5::+JU1&C?/0T*+"**1#*<0A%
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M@IH\),7SX#V4@'JWL/38;C(#B -"I]LA0) ,0LTHGR#-6<3%,Z\][C#C6SD
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M^MO :+?,O*E)39H&A0;$V5O\ @0>JD"U.C[49BR?%_/40^,JFQN/GA:/6![
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MM3,&9^$Z0$D9&)DWH5[,<\OP!/X:8F<]&CQ#)Q\2DXG3ORI*CAQK&DHDV"O
M72?X>%?HF^Z&2=!SIS-BC^=*TW[V1.<>W!<RNBP,U.+91:#*H20#XQ09)4\
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M6((B33!8<?V+N&.T]W!V-?; !RIU*Y'B[$OXC C!)*J9['F?@Q4K^[!(UV]
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MS//B,8)S8#78&5NKNGV3.8L;!"9?1>(Z PL!P10D3["@<A,(%)PZKFZ"/;F
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M)CY^@WDG-Z6;^3\XW<GX;%-YU]\UW>X)6WQ$&1KW<"E23[L6L-R]Q6"*K92
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MCEI*<KA:84M',](2U*M)&HF0Y3XRA/D!%A[W/O;+WGM08]>,: <P&V9>_(%
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MQYDY<S,%Y<3'Z]<K4# A#2Q+'5]X:,8+2)'9[W2!3 ?.,[[!&;T,EY:E?I$
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M;?*;(G;$33[.!FY/^TD5BO-E2BO+%3@ A)\PI5X!.G*.6?T,R@\I9F*LY^7
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M(A2H0/=Z02MQ3?KM=#A'_'*HB @M@)BZN\-5^!O=0@PS^VJ4!-FTY0'QQF
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M O+3(URY;X\.Y 5G  SKIR/IAMD>CV1U'VTG6_O0RKW_?/3L>H>%-V#F$=I
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M1U;63P8P@WZ/&?L %IIEQ:6^D/12&-3JNS O/*DJ3B>LY+!R+<).SHE^$<^
MM<_P!;[>01H</N K15&U2,:H]4] .>=MBA>+#/2X4=9Z,G"JEVDI(F:*FU-&
M8.^?P\8:GCL^3T!!FI3Q)3'7./H A @[ !M5PY"C.$?U*4LJEE;X=?I!U]OO
M+<IBG$R6,(Z9G[]_8]!9$]BR**W\1S:N8!<^@P<_WB_@(@+%9VVKI'WM]T9H
M^X!T*M%<R0O=;[P#\V0"_\3)S)8Q;FB2$)V37A+5JP6]T/X.?@5J2UR*1"7B
MQ_>T;;$=%2=;H\RJD,: /N "Y2NDZ)GJ.W(W4<J7<;EJ(0]4EYQWXC<6YZL*
M=?4,+VQ9)DU=-KCR2[#:,N?50+I E,K30!C#.'*= P*++^#>TUD8/=VH0/HH
MOFN4)-;"HZ.<+K-,V!]*?D25FJOK][9;P)3H-!\G6<9,[E(90XDG]RA@ [(6
MOHDZ V))'21#MJU<1-YC9_3=Z 2X-IJ1ND 9P9DO[-4RJW$"R.1E8ROFM6 \
MT9QE5C404N8P)W_'@41:MCQ0BY/I% TI^#)<(N!5PGF*9:V4UOE^G5PP ,P:
MU#'0 (%4V  R.IES'S>]%$G^S!ZQ$HJ>(J\")$E.FGN9@&4Y 0YP;IEG8P0P
ML8(AS&N5T59+.%VSYSP#?TAEL23^R C%\T [M/T."W6A^;CSP-!6OP?$A<\1
MHK*HS=@YO0$TJX,7P>K)8B" )4E8SQZ/DT6-E!R2$&@%XX]Y<0EZ[HRE?(QJ
MOL Y\%4P[2NB(H8_@,E>I!6#*_(F4"[@._'B?!B()*.]M-%C<)2!/=YYY(9,
M^[TI6SL\A,,G6,N9P=;GK.N(9B2R(Q9^ST17U62D"*@TC<?\JF*Z>ZW0>X>Z
M&"$>D4Y7MZ6>VO',2/_G_OWH59IDDZ?1^V66W#^)@0[NWW_Q_/#X)YT$O_I^
M72SH]3K6_5%1U\5</A- ^.&3/][SONP"3_B<H-STLH,,J"]ZL/L$9EL563JQ
M&P%O>"%_.E/\SIOC+6^5]0&XF'_H$_C,V6RWN^@H@!FMA<T[EH$+"%T#>V2K
M$;;=_-WNP\:>H'D3(H?^EYM/'^<5S-&R3H)1TDH$(X*G3P;1"O1L5-J17U:@
MD0B7Z/=:H=0ALR$TL)E/I<(2:0!X-VHOL2N<424PTTCGH(BE\&BV<CB6\_2N
M^!,(\+]6L/\WP0?P>CV#U_UKF8#$@%'YKI%WI8,K/'C80KC?.]==/VNY\7:1
MSM3=G6 VT)S "&33Q_MLCSX%,82S=B?U?<N<<*)7'=+E/[?+>NX:M!BU@!9D
M&0I>@7J',3@9_UZPWGA%\!MTF#_L[?[Y"0K=X2;(/C3GK3IMYF9L^;O;N[L^
MN[$]NY=J+'L('##7*6I+9!T0)N2@!ZP$,;3,'%74?^3893)+JUI\,Z1!T0'Q
MQV08#"-!#H!1HZE=+QE3C@G5J,4,94[MVAX*.*15M;3J:D-;%!N!55[2&/,F
M&!9G54&.%;4/NV$Q%!Z@W^(FC%:"B9/2*D360!L4/D]=,\\SH'%@\5KB=,4=
M"J_L5&U]^P=>7Z>XJ\5(=@W!M12D'@JI?^[LWS\81#M_'_P/?KZS/T"L&W;U
MZ1=#\+\_;>G!9VE+<#:\,W]U8A76:DP$W1GS]VFT(\CB3S_OGZBEXF@KKCZ#
M*!A0VB1$!3=C=*I"M?VJ(GL4=OC<@K=H*EKH NPPO+#$L@5PZ_<>[L0#920$
MZ4WBE5'_&BH:WDE$5J\X3-08Q7TG>=?-G2H6"?KU<'%RL8%E+3-0/6OYSGD!
M(^CE#H!8-#VB[_?V=D8$Q+VGK](4WKXY148W7V8SLB95T@$_2^!?H+Y6QEW8
M[V7Q947^?-IO3TDE$%E8<K%PS65E=4E*6.'.:FN2B%HI@JWY]22!!_)O'N<@
MG0@D+//Q)+M, #8['Z<+6*Y.Y4U<?DQJI.<R0?N?N=A!5A3( V?1Z]T3$$.Q
M@<Y4#-D5&WR8*<+9D5]#SH:\)DN"L7QJ@+UI(X<&<2%M>@">PH/B(Z!O.^$1
M<+SY.%O2]P4;]9ZT3IAQ5J ZLR6=AA,;;+XG.)>TA:VT\XM^KWV'&W!8^VXW
M=VW-PVNN/S"W#>L*=G#;B]YR%Y_=K GX8.\1FD";).O]1V0I?9.M7;+U8'O9
M:H9O";!I044K,3W$B4@L_1EZ4B8W3!G;:%SWU<TN!'%-X==7G\ WNFRGR[]?
M6>=;BWJ3TG19++,)VA5D'*'<HV!(ZP -O4/H71FCLX,L*1/%PH%1C8>%A1L+
M\!(M/]\:0C/(/@#V'[DM$5&/C4.VW],';AA%^Y4L]$[FL W:]O!9](Y4O^HI
M3D7$W+/H)PRKA5_?%ABW_;XTP^>WNK+W/&1?-^!9=+9:8-AX&8_2\;/H;3Q/
M>)/>%KCTAQX<I]\BC\7O'BIL([?HMFG^2I" 8'1NT/((:&Y6%B!0,=.A*)\B
M@E(G%#,&9D83Q&,.-)1PXA5IG$,U.,88RUE3')*-5)RF956K&FL1_G$6+ROE
MIJ3=8N(#JH]ITZ@AWSP!2UE*6@",CI@,.POCP,3A^8S 2EIT6DF*;9&1 [P9
M*+?BZ&;Y19X@LZ\=@PV7BG''OH$G5I478N"-U#GSM898M#,B1W?#SJ$@QA^>
M/MH#]:<S/ATT\L=/]QYV1[ /P+P=T5:_.WOY_PYP5OB/OS?! '=++XIL.4=A
MA %PN (0YW"O$.=8M\_6&[1A<RF0TY^/A[[ I,>M]&' R_:=IL.6];0,@9;C
ME&FE,H3AO3[F&+O<'AC\"O'VDS3_"!("?B-TL(,(1QQ5Z3Q%"\>-P:70OADP
M2 S9&8\3@0$*2L&8+G.)]J7@ O+/PV]Y4@/>_GE1U81=@H9@J=O#^.W,^SV>
M>E6821,.O#,9D"Z"X3ZD,F!43C44CWM:(I/!A7#B"&D:[1X$PF/<RPZ:!W*<
M14)L!X^MC$'S@/VHD@P$)P,WLZ*8X$"@_PB#.+%AU#3<//ZE*)%2$91& 998
M_N%$>M-YN.$N>(X<( &T8L(L4#5CQ*G?,S'-C 8E'"R8?((I2Z0.WV$#&B_B
MU/ QC02Z[HRWWYPOP_IZ$*QP9$._=R?"03ELO[>]<)C$*9!(!S_;(#:V8&?]
MGN%G=R@K^CTC+*)?+2N8ZCY/8O1[U[_%5Y<8=/]#D=&QWS<K,?J]0&1$=R,Q
MQ$H-IMXB,?CP;TIL8.!RB]R(UHN-[?18*UR$;W?+&+,;OT;(1-<A8[9;VC=)
MM-T^'4_[O3!PL63@AFF+N$W<C&(7T86!O_B=SM#,-FQ' ?%'(+1V?M!,"4H6
M5-K:'PN3# /ZB3+J^&.B\D-]^3!=(.8R'J-?'\R5L?'5R"LP"!NIU'C9=YU
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MVE.YRS+G-]'O\\L3\FTM[8(JV(C=G(# >P\"K]\[=(UXEO"'W-C9D$A8$#
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MYHZN!,O=%?Y'1!NO*.V=U*3=)#K<SDJP\^+P72PHG"9Q+8NA%20LK$RA5%*
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M($*+KH/.C('F%A-G0ON5!'-U>L&8*B(88Y![Y$)5U&SI,W+K;K_QJM/I"Z@
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MA3$HI)U]Z!3N#/))3BH!H?6">7>I,JG0-WF6)5[^0(1X!5<L-5 Q8-5Y;G/
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MY9GZ&B:5GKJ$@=9*'SH-H$_[;X5+#3"#1A&7^+1^E58*-\H8$".<@4^0V9Y
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M"P\KPSE';<5DKK@J3<3"S^I$K";D<RMCF[X?Z;\P2=^K_#]02P,$%     @
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M\W5U5T FN!]<ETJZUC5VG\Q6DA"=('*264^*@BB=K/4!!R((%4/TV22IG*
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M_-O,]IQ^5SC\\C#]CO%_ 5!+ P04    " "X@IY8@$H:<6\,  #T)   '
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MOT7EC<!X27^U%/^,B?[:Z=]02P$"% ,4    " "X@IY8[_0B_BT#  #O"P
M$0              @ $     8W1X<BTR,#(T,#0R-2YX<V102P$"% ,4
M" "X@IY8+1,-B?T*  " A@  %0              @ %< P  8W1X<BTR,#(T
M,#0R-5]L86(N>&UL4$L! A0#%     @ N(*>6'2*EK5<!P  W5<  !4
M         ( !C X  &-T>'(M,C R-# T,C5?<')E+GAM;%!+ 0(4 Q0    (
M +B"GE@RT[5[C!H  &Z3   7              "  1L6  !E83 R,#0X.3(M
M.&M?8VET:75S+FAT;5!+ 0(4 Q0    ( +B"GEB(VE55 YT  ,E0 P <
M          "  =PP  !E83 R,#0X.3(P,65X,3 M,5]C:71I=7,N:'1M4$L!
M A0#%     @ N(*>6/AR'EB&2   +'L! !L              ( !&<X  &5A
M,#(P-#@Y,C Q97@T+3%?8VET:75S+FAT;5!+ 0(4 Q0    ( +B"GEB)9=>Q
ME0H  %XI   ;              "  =@6 0!E83 R,#0X.3(P,65X-2TQ7V-I
M=&EU<RYH=&U02P$"% ,4    " "X@IY8%.-XBL,-  !J+   '
M    @ &F(0$ 96$P,C T.#DR,#%E>#DY+3%?8VET:75S+FAT;5!+ 0(4 Q0
M   ( +B"GEB 2AIQ;PP  /0D   <              "  :,O 0!E83 R,#0X
K.3(P,65X.3DM,E]C:71I=7,N:'1M4$L%!@     )  D >@(  $P\ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>ea0204892-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20240425.xsd" xlink:type="simple"/>
    <context id="AsOf2024-04-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-04-25" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-04-25" id="Fact000004">0001506251</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-04-25" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-04-25" id="Fact000010">2024-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-04-25" id="Fact000011">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-04-25" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-04-25" id="Fact000013">001-38174</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-04-25" id="Fact000014">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-04-25" id="Fact000015">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-04-25" id="Fact000016">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-04-25" id="Fact000017">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-04-25" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-04-25" id="Fact000019">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-04-25" id="Fact000020">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-04-25" id="Fact000021">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-04-25" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-04-25" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-04-25" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-04-25" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-04-25" id="Fact000026">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-04-25" id="Fact000027">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-04-25" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-04-25" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
